Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort.

Zhu P, Zhu Q, Zhang Y, Ma X, Li Z, Li J, Chen J, Luo L, Ring HZ, Ring BZ, Su L.

PLoS One. 2013;8(1):e55197. doi: 10.1371/journal.pone.0055197. Epub 2013 Jan 25.

2.

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.

AIDS. 2007 Oct 18;21(16):2191-9.

PMID:
18090046
3.

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.

Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Aklillu E, Burhenne J.

PLoS One. 2013 Jul 5;8(7):e67946. doi: 10.1371/journal.pone.0067946. Print 2013.

4.

Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.

Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, van Schaik RH.

Ther Drug Monit. 2012 Apr;34(2):153-9. doi: 10.1097/FTD.0b013e31824868f3.

PMID:
22354160
5.

CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.

Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.

J Acquir Immune Defic Syndr. 2010 Jul;54(3):285-9. doi: 10.1097/QAI.0b013e3181bf648a.

6.

Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs.

Zhou F, Kominski GF, Qian HZ, Wang J, Duan S, Guo Z, Zhao X.

BMC Med. 2011 Jan 17;9:6. doi: 10.1186/1741-7015-9-6.

7.

Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.

Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Shioda T, Khusmith S.

Southeast Asian J Trop Med Public Health. 2012 Jan;43(1):78-88.

PMID:
23082557
8.

The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China.

Zhang F, Dou Z, Yu L, Xu J, Jiao JH, Wang N, Ma Y, Zhao Y, Zhao H, Chen RY.

Clin Infect Dis. 2008 Sep 15;47(6):825-33. doi: 10.1086/590945.

9.

CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.

Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, van den Anker JN.

Ther Drug Monit. 2011 Aug;33(4):417-24. doi: 10.1097/FTD.0b013e318225384f.

10.

Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial.

Gozalo C, Gérard L, Loiseau P, Morand-Joubert L, Peytavin G, Molina JM, Dellamonica P, Becquemont L, Aboulker JP, Launay O, Verstuyft C; ANRS 081 Study Group.

Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):513-20. doi: 10.1111/j.1742-7843.2011.00780.x. Epub 2011 Sep 6.

11.

ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients.

Coelho AV, Silva SP, de Alencar LC, Stocco G, Crovella S, Brandão LA, Guimarães RL.

J Clin Pharmacol. 2013 Dec;53(12):1286-93. doi: 10.1002/jcph.165. Epub 2013 Sep 17.

PMID:
23996099
12.

Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.

Li T, Dai Y, Kuang J, Jiang J, Han Y, Qiu Z, Xie J, Zuo L, Li Y.

PLoS One. 2008;3(12):e3918. doi: 10.1371/journal.pone.0003918. Epub 2008 Dec 12.

13.

[Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].

Han XX, Zhang M, Cui WG, Liu BG, Wang Yn, Zhang ZN, Liu J, Geng WQ, Diao YY, Dai D, Jiang YJ, Shang H.

Zhonghua Yi Xue Za Zhi. 2005 Mar 23;85(11):760-4. Chinese.

PMID:
15949383
14.

Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children.

Bellusci CP, Rocco C, Aulicino P, Mecikovsky D, Curras V, Hegoburu S, Bramuglia GF, Bologna R, Sen L, Mangano A.

Gene. 2013 Jun 10;522(1):96-101. doi: 10.1016/j.gene.2013.03.020. Epub 2013 Mar 23.

PMID:
23528223
15.

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.

Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V.

Pharmacogenomics. 2010 Sep;11(9):1223-34. doi: 10.2217/pgs.10.94.

PMID:
20860463
16.

Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.

Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S, Di Perri G.

Br J Clin Pharmacol. 2012 Jul;74(1):134-40. doi: 10.1111/j.1365-2125.2012.04163.x.

17.
19.

ABCB1 allele polymorphism is associated with virological efficacy in naïve HIV-infected patients on HAART containing nonboosted PIs but not boosted PIs.

de la Tribonnière X, Broly F, Deuffic-Burban S, Bocket L, Ajana F, Viget N, Melliez H, Mouton Y, Yazdanpanah Y.

HIV Clin Trials. 2008 May-Jun;9(3):192-201. doi: 10.1310/hct0903-192.

PMID:
18547906
20.

Supplemental Content

Support Center